Archives
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
br Acknowledgements We would like to thank Dr Thomas
2023-03-11

Acknowledgements We would like to thank Dr. Thomas Blanpied, Sai Sachin Divakaruni, Dr. Helmut Kessels, Feline Lindhout, Dieudonnée van de Willige, and all members of the MacGillavry lab for discussions and critical reading of the manuscript. This work was supported by NWO (ALW-VENI 863.13.020, A
-
br Conflict of interest br Introduction Platelets
2023-03-11

Conflict of interest Introduction Platelets are anucleate blood cells essential for hemostasis and wound healing; tight regulation of platelet numbers is crucial for human health. Platelets are synthesized and released from bone marrow megakaryocytes into the circulation where they remain for
-
Most human diseases e g cancer diabetes and
2023-03-10

Most human diseases (e.g., cancer, diabetes, and neurodegenerative diseases) are complex and multifactorial. Several investigations in the literature focused on new multi-target drug development, which implies active pharmacophores incorporation in one scaffold (Meunier, 2008, Lazar et al., 2004, Te
-
Most human diseases e g cancer diabetes and
2023-03-10

Most human diseases (e.g., cancer, diabetes, and neurodegenerative diseases) are complex and multifactorial. Several investigations in the literature focused on new multi-target drug development, which implies active pharmacophores incorporation in one scaffold (Meunier, 2008, Lazar et al., 2004, Te
-
Most human diseases e g cancer diabetes and
2023-03-10

Most human diseases (e.g., cancer, diabetes, and neurodegenerative diseases) are complex and multifactorial. Several investigations in the literature focused on new multi-target drug development, which implies active pharmacophores incorporation in one scaffold (Meunier, 2008, Lazar et al., 2004, Te
-
Most human diseases e g cancer diabetes and
2023-03-10

Most human diseases (e.g., cancer, diabetes, and neurodegenerative diseases) are complex and multifactorial. Several investigations in the literature focused on new multi-target drug development, which implies active pharmacophores incorporation in one scaffold (Meunier, 2008, Lazar et al., 2004, Te
-
Several ceritinib resistant mutations following the second l
2023-03-08

Several ceritinib-resistant mutations following the second-line treatment of ALK+-NSCLC have been discovered [64]. These mutations include C1156Y, F1174L, and L1152R, which were first observed in crizotinib-resistant tumor samples. The G1202R ceritinib-resistant mutation occurs within the hinge and
-
The AhR molecule is composed of multiple functional domains
2023-03-08

The AhR molecule is composed of multiple functional domains [38]. In the N-terminal end, the AhR contains bHLH domain which is involved in DNA binding, dimerization with ARNT and association with chaperone proteins. The PAS domain, which is situated next to the bHLH domain consists of two structural
-
br Conclusion br Conflict of Interest br Author Contribution
2023-03-08

Conclusion Conflict of Interest Author Contributions Acknowledgements This work was supported by a research grant (SR/50/AS-14/2012) from the Department of Science and Technology, New Delhi, India to CMC and CSIR Senior Research Fellowship (09/013(0339)/2010-EMR-I) to SB. Introduction
-
br Adenosine as a mediator of procedures used to manage
2023-03-08

Adenosine as a mediator of procedures used to manage pain The issue of caffeine Caffeine, from dietary sources, is perhaps the most widely consumed behaviorally active agent in the world (Fredholm et al., 1999). Initial characterization indicated caffeine had a higher affinity at A1−, A2A− and
-
Moreover our results indicate that ADP is by
2023-03-08

Moreover, our results indicate that ADP is by far a better phosphate donor than AMP (Table 2). Yet, the bindings of AMP and ATP are mutually exclusive, whereas the bindings of ADP and ATP are additive (Fig. 7). The multiplicity of the phosphate donors in the TgAK reaction (Tables 1 & 2), suggests th
-
Luciferase Immunoprecipitation Systems LIPS which utilizes r
2023-03-08

Luciferase Immunoprecipitation Systems (LIPS), which utilizes recombinant antigens fused to the enzyme reporter Renilla luciferase (Ruc) to detect patient antibodies, provides a unique platform to investigate Psalmotoxin 1 directed against a variety of antigenic targets [25]. Previously, LIPS has b
-
To reconstruct the amino acid sequence of
2023-03-08

To reconstruct the amino Splitomicin sequence of an ancestral β subunit a molecular phylogeny is required, which is inferred from a β subunit sequence alignment. To build this alignment we searched the NCBI database for proteins similar in sequence to the human muscle-type β subunit precursor prote
-
Our co IP data show that HT A
2023-03-07

Our co-IP data show that 5HT1A or 5HT2A receptors do not heterodimerize with mGluR1α receptors. Given that both 5-HT and mGlu receptors are GPCRs and produce anxiolytic effects, a degree of cooperativity via a functional cross-talk may still exist between these receptors [11]. In addition to the fun
-
Consistent with a damaging role for increased LOX
2023-03-06

Consistent with a damaging role for increased 12/15-LOX activity in stroke, systemic administration of the 12/15-LOX inhibitor, LB1, 2 h after permanent focal cerebral ischemia significantly reduced infarct size 24 h after the ischemia, and the treatment group demonstrated improved behavioral and he
16793 records 374/1120 page Previous Next First page 上5页 371372373374375 下5页 Last page